CAS 945228-48-8
:Oportuzumab monatox
Description:
Oportuzumab monatox is a monoclonal antibody conjugate designed for targeted cancer therapy. It is specifically engineered to bind to the epithelial cell adhesion molecule (EpCAM), which is overexpressed in various epithelial tumors. The compound is linked to a cytotoxic agent, allowing it to deliver a lethal dose of the drug directly to cancer cells while minimizing damage to surrounding healthy tissue. This targeted approach enhances the therapeutic efficacy and reduces systemic side effects commonly associated with traditional chemotherapy. Oportuzumab monatox has been investigated primarily for its potential use in treating solid tumors, including breast and colorectal cancers. Its mechanism of action involves the internalization of the antibody-drug conjugate upon binding to EpCAM, leading to cell death through the release of the cytotoxic agent. As a biopharmaceutical, it undergoes rigorous clinical testing to evaluate its safety, efficacy, and optimal dosing regimens. Overall, Oportuzumab monatox represents a promising advancement in the field of targeted cancer therapies.
Formula:Unspecified
Synonyms:- Vicinium
- Protein VB4-845 (synthetic)
- Vicineum
- Oportuzumab monatox
- Immunoglobulin G, anti-(tumor antigen 17-1A) (human-mouse single chain fragment) fusion protein with 252-608-exotoxin A (synthetic Pseudomonas)
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 2 products.
Oportuzumab Monatox
CAS:<p>Antibody-drug conjugate (ADC) a humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM and a truncated portion of Pseudomonas exotoxin A.</p>Oportuzumab
CAS:<p>Antibody-drug conjugate (ADC) a humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM and a truncated portion of Pseudomonas exotoxin A.</p>
